Medullary carcinoma of the thyroid gland
One hundred thirty‐nine surgically treated patients with medullary carcinoma of the thyroid gland (MTC) were seen in our institution between January, 1926 and December, 1973. The incidence of this tumor among all thyroid cancers was 8%. Twenty‐nine patients had the familial form of MTC; they were su...
Gespeichert in:
| Veröffentlicht in: | Cancer 1975-03, Vol.35 (3), p.695-704 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 704 |
|---|---|
| container_issue | 3 |
| container_start_page | 695 |
| container_title | Cancer |
| container_volume | 35 |
| creator | Chong, Guan C. Beahrs, Oliver H. Sizemore, Glen W. Woolner, Lewis H. |
| description | One hundred thirty‐nine surgically treated patients with medullary carcinoma of the thyroid gland (MTC) were seen in our institution between January, 1926 and December, 1973. The incidence of this tumor among all thyroid cancers was 8%. Twenty‐nine patients had the familial form of MTC; they were sub‐classified, on the basis of the phenotype, into a group of 15 patients with Sipple syndrome (or multiple endocrine neoplasia (MEN) Type 2A) and a group of 14 patients with mucosal‐neuroma phenotype (or MEN type 2B). Better survivorship was seen in the younger patients, in those with bilateral tumors, in familial MTC, and in patients whose tumor was confined to the thyroid gland at the initial surgery. The incidence of tumor recurrence was 34%. However, in those with adequate surgical treatment, the recurrence was only 23%. The 5‐and 10‐year survivorships were 80% and 67%, respectively. The best chance of cure lies in early diagnosis through the use of immunoreactive calcitonin measurement in family members at risk, and an aggressive surgical attack on the primary tumor and any cervical metastases. |
| doi_str_mv | 10.1002/1097-0142(197503)35:3<695::AID-CNCR2820350323>3.0.CO;2-W |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_82803633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>82803633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3793-c60c81f49fae1a0cf3d7010471c8b37e88bd5fa15234126e63a07e2338d565483</originalsourceid><addsrcrecordid>eNqVkF1LwzAUhoMoOj9-grArmRedJzlNk04RpX7CdCCKuztkaaqVbp3thuzfm9Gh6IVgIITwnLzn5GHsjEOXA4gjDrEKgIeiw2MlAQ9R9vAkimWvd357EST3yYPQAtAjgafYhW4yOBbB8xprfT1dZy0A0IEMcbjFtuv6zV-VkLjJNrlfMaoW69y5dF4Uplq0ralsPinHpl1m7dmr83tRlXnafinMJN1lG5kpare3OnfY09XlY3IT9AfXt8l5P7CoYgxsBFbzLIwz47gBm2GqgEOouNUjVE7rUSozw6XAkIvIRWhAOYGoUxnJUOMOO2hyp1X5Pnf1jMZ5bZ0fceLKeU1aaMAI0RcOm0JblXVduYymVT72HyEOtJRISxO0NEGNREJJSF4ikZdIPyV6ApQMSNCzj95fzTAfjV36HdxY89w2_CMv3OIfff9s-4vgJypGi-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>82803633</pqid></control><display><type>article</type><title>Medullary carcinoma of the thyroid gland</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Chong, Guan C. ; Beahrs, Oliver H. ; Sizemore, Glen W. ; Woolner, Lewis H.</creator><creatorcontrib>Chong, Guan C. ; Beahrs, Oliver H. ; Sizemore, Glen W. ; Woolner, Lewis H.</creatorcontrib><description>One hundred thirty‐nine surgically treated patients with medullary carcinoma of the thyroid gland (MTC) were seen in our institution between January, 1926 and December, 1973. The incidence of this tumor among all thyroid cancers was 8%. Twenty‐nine patients had the familial form of MTC; they were sub‐classified, on the basis of the phenotype, into a group of 15 patients with Sipple syndrome (or multiple endocrine neoplasia (MEN) Type 2A) and a group of 14 patients with mucosal‐neuroma phenotype (or MEN type 2B). Better survivorship was seen in the younger patients, in those with bilateral tumors, in familial MTC, and in patients whose tumor was confined to the thyroid gland at the initial surgery. The incidence of tumor recurrence was 34%. However, in those with adequate surgical treatment, the recurrence was only 23%. The 5‐and 10‐year survivorships were 80% and 67%, respectively. The best chance of cure lies in early diagnosis through the use of immunoreactive calcitonin measurement in family members at risk, and an aggressive surgical attack on the primary tumor and any cervical metastases.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(197503)35:3<695::AID-CNCR2820350323>3.0.CO;2-W</identifier><identifier>PMID: 1111937</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adolescent ; Adult ; Age Factors ; Aged ; Calcitonin - blood ; Calcitonin - immunology ; Carcinoma - diagnosis ; Carcinoma - genetics ; Carcinoma - surgery ; Child ; Child, Preschool ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Neoplasms, Multiple Primary ; Parathyroid Neoplasms - complications ; Phenotype ; Prognosis ; Thyroid Neoplasms - diagnosis ; Thyroid Neoplasms - genetics ; Thyroid Neoplasms - surgery</subject><ispartof>Cancer, 1975-03, Vol.35 (3), p.695-704</ispartof><rights>Copyright © 1975 American Cancer Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3793-c60c81f49fae1a0cf3d7010471c8b37e88bd5fa15234126e63a07e2338d565483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1111937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chong, Guan C.</creatorcontrib><creatorcontrib>Beahrs, Oliver H.</creatorcontrib><creatorcontrib>Sizemore, Glen W.</creatorcontrib><creatorcontrib>Woolner, Lewis H.</creatorcontrib><title>Medullary carcinoma of the thyroid gland</title><title>Cancer</title><addtitle>Cancer</addtitle><description>One hundred thirty‐nine surgically treated patients with medullary carcinoma of the thyroid gland (MTC) were seen in our institution between January, 1926 and December, 1973. The incidence of this tumor among all thyroid cancers was 8%. Twenty‐nine patients had the familial form of MTC; they were sub‐classified, on the basis of the phenotype, into a group of 15 patients with Sipple syndrome (or multiple endocrine neoplasia (MEN) Type 2A) and a group of 14 patients with mucosal‐neuroma phenotype (or MEN type 2B). Better survivorship was seen in the younger patients, in those with bilateral tumors, in familial MTC, and in patients whose tumor was confined to the thyroid gland at the initial surgery. The incidence of tumor recurrence was 34%. However, in those with adequate surgical treatment, the recurrence was only 23%. The 5‐and 10‐year survivorships were 80% and 67%, respectively. The best chance of cure lies in early diagnosis through the use of immunoreactive calcitonin measurement in family members at risk, and an aggressive surgical attack on the primary tumor and any cervical metastases.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Calcitonin - blood</subject><subject>Calcitonin - immunology</subject><subject>Carcinoma - diagnosis</subject><subject>Carcinoma - genetics</subject><subject>Carcinoma - surgery</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasms, Multiple Primary</subject><subject>Parathyroid Neoplasms - complications</subject><subject>Phenotype</subject><subject>Prognosis</subject><subject>Thyroid Neoplasms - diagnosis</subject><subject>Thyroid Neoplasms - genetics</subject><subject>Thyroid Neoplasms - surgery</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1975</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkF1LwzAUhoMoOj9-grArmRedJzlNk04RpX7CdCCKuztkaaqVbp3thuzfm9Gh6IVgIITwnLzn5GHsjEOXA4gjDrEKgIeiw2MlAQ9R9vAkimWvd357EST3yYPQAtAjgafYhW4yOBbB8xprfT1dZy0A0IEMcbjFtuv6zV-VkLjJNrlfMaoW69y5dF4Uplq0ralsPinHpl1m7dmr83tRlXnafinMJN1lG5kpare3OnfY09XlY3IT9AfXt8l5P7CoYgxsBFbzLIwz47gBm2GqgEOouNUjVE7rUSozw6XAkIvIRWhAOYGoUxnJUOMOO2hyp1X5Pnf1jMZ5bZ0fceLKeU1aaMAI0RcOm0JblXVduYymVT72HyEOtJRISxO0NEGNREJJSF4ikZdIPyV6ApQMSNCzj95fzTAfjV36HdxY89w2_CMv3OIfff9s-4vgJypGi-g</recordid><startdate>197503</startdate><enddate>197503</enddate><creator>Chong, Guan C.</creator><creator>Beahrs, Oliver H.</creator><creator>Sizemore, Glen W.</creator><creator>Woolner, Lewis H.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197503</creationdate><title>Medullary carcinoma of the thyroid gland</title><author>Chong, Guan C. ; Beahrs, Oliver H. ; Sizemore, Glen W. ; Woolner, Lewis H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3793-c60c81f49fae1a0cf3d7010471c8b37e88bd5fa15234126e63a07e2338d565483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1975</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Calcitonin - blood</topic><topic>Calcitonin - immunology</topic><topic>Carcinoma - diagnosis</topic><topic>Carcinoma - genetics</topic><topic>Carcinoma - surgery</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasms, Multiple Primary</topic><topic>Parathyroid Neoplasms - complications</topic><topic>Phenotype</topic><topic>Prognosis</topic><topic>Thyroid Neoplasms - diagnosis</topic><topic>Thyroid Neoplasms - genetics</topic><topic>Thyroid Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chong, Guan C.</creatorcontrib><creatorcontrib>Beahrs, Oliver H.</creatorcontrib><creatorcontrib>Sizemore, Glen W.</creatorcontrib><creatorcontrib>Woolner, Lewis H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chong, Guan C.</au><au>Beahrs, Oliver H.</au><au>Sizemore, Glen W.</au><au>Woolner, Lewis H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medullary carcinoma of the thyroid gland</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1975-03</date><risdate>1975</risdate><volume>35</volume><issue>3</issue><spage>695</spage><epage>704</epage><pages>695-704</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>One hundred thirty‐nine surgically treated patients with medullary carcinoma of the thyroid gland (MTC) were seen in our institution between January, 1926 and December, 1973. The incidence of this tumor among all thyroid cancers was 8%. Twenty‐nine patients had the familial form of MTC; they were sub‐classified, on the basis of the phenotype, into a group of 15 patients with Sipple syndrome (or multiple endocrine neoplasia (MEN) Type 2A) and a group of 14 patients with mucosal‐neuroma phenotype (or MEN type 2B). Better survivorship was seen in the younger patients, in those with bilateral tumors, in familial MTC, and in patients whose tumor was confined to the thyroid gland at the initial surgery. The incidence of tumor recurrence was 34%. However, in those with adequate surgical treatment, the recurrence was only 23%. The 5‐and 10‐year survivorships were 80% and 67%, respectively. The best chance of cure lies in early diagnosis through the use of immunoreactive calcitonin measurement in family members at risk, and an aggressive surgical attack on the primary tumor and any cervical metastases.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>1111937</pmid><doi>10.1002/1097-0142(197503)35:3<695::AID-CNCR2820350323>3.0.CO;2-W</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1975-03, Vol.35 (3), p.695-704 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_82803633 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Age Factors Aged Calcitonin - blood Calcitonin - immunology Carcinoma - diagnosis Carcinoma - genetics Carcinoma - surgery Child Child, Preschool Female Humans Male Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local Neoplasms, Multiple Primary Parathyroid Neoplasms - complications Phenotype Prognosis Thyroid Neoplasms - diagnosis Thyroid Neoplasms - genetics Thyroid Neoplasms - surgery |
| title | Medullary carcinoma of the thyroid gland |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T02%3A06%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medullary%20carcinoma%20of%20the%20thyroid%20gland&rft.jtitle=Cancer&rft.au=Chong,%20Guan%20C.&rft.date=1975-03&rft.volume=35&rft.issue=3&rft.spage=695&rft.epage=704&rft.pages=695-704&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/1097-0142(197503)35:3%3C695::AID-CNCR2820350323%3E3.0.CO;2-W&rft_dat=%3Cproquest_cross%3E82803633%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=82803633&rft_id=info:pmid/1111937&rfr_iscdi=true |